In Reply
- PMID: 34794159
- DOI: 10.1097/AOG.0000000000004623
In Reply
Conflict of interest statement
Financial Disclosure Ben W. Mol reports a grant was paid to his institution: NHMRC Investigator Grant (GNT1176437). He has been a consultant for ObsEva, Guerbet, Merck, and Merck KGaA. The other authors did not report any potential conflicts of interest.
Comment on
-
Assessing Research Misconduct in Randomized Controlled Trials.Obstet Gynecol. 2021 Sep 1;138(3):338-347. doi: 10.1097/AOG.0000000000004513. Obstet Gynecol. 2021. PMID: 34352811 Review.
-
Assessing Research Misconduct in Randomized Controlled Trials.Obstet Gynecol. 2021 Dec 1;138(6):944. doi: 10.1097/AOG.0000000000004622. Obstet Gynecol. 2021. PMID: 34794158 No abstract available.
References
REFERENCE
-
- Li W, Bordewijk EM, Mol BW. Assessing research misconduct in randomized controlled trials. Obstet Gynecol 2021;138:338–47. doi: 10.1097/AOG.0000000000004513. - DOI
Publication types
LinkOut - more resources
Full Text Sources